Home > Insider Trading > Filing (0001610717-25-000049)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1770787	10X Genomics Inc.	TXG	Laboratory Analytical Instruments (3826)	455614458

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786720	Serge Saxonov	10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2025-02-28	7,942	$10.63	871,540	No	4	S	Direct
Class A Common Stock	Acquisiton	2025-03-04	50,000	$1.20	921,540	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Disposition	2025-03-04	50,000	$0.00	50,000	$1.20

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,463		2027-10-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	27	Indirect	See footnote
Class A Common Stock	870	Indirect	See footnote
Class A Common Stock	213,250	Indirect	See footnote
Class A Common Stock	22,570	Indirect	See footnote

Footnotes

The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 12, 2024 and terminated effective March 4, 2025.
This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.